CN101821235B - 作为雄激素受体调节剂的吡咯烷-2-酮衍生物 - Google Patents
作为雄激素受体调节剂的吡咯烷-2-酮衍生物 Download PDFInfo
- Publication number
- CN101821235B CN101821235B CN2008801105925A CN200880110592A CN101821235B CN 101821235 B CN101821235 B CN 101821235B CN 2008801105925 A CN2008801105925 A CN 2008801105925A CN 200880110592 A CN200880110592 A CN 200880110592A CN 101821235 B CN101821235 B CN 101821235B
- Authority
- CN
- China
- Prior art keywords
- compound
- mixture
- ethyl
- added
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCOC(C(C)(C)C([C@@](C)NC(OCC1=CC=CCC1)=O)O*(C)(C)C(C)(C)C)=O Chemical compound CCOC(C(C)(C)C([C@@](C)NC(OCC1=CC=CCC1)=O)O*(C)(C)C(C)(C)C)=O 0.000 description 2
- GVAQHXNKGBAPGR-UHFFFAOYSA-N CC(C)C(C(O)=O)Nc(cc1Cl)ccc1C#N Chemical compound CC(C)C(C(O)=O)Nc(cc1Cl)ccc1C#N GVAQHXNKGBAPGR-UHFFFAOYSA-N 0.000 description 1
- XRJRDUTWAOVSEZ-VZJVUDMVSA-N CC(C)C[C@@H]([C@@H]([C@H](C)N1C(CC2)=CC(Cl)=C2C#N)O)C1=O Chemical compound CC(C)C[C@@H]([C@@H]([C@H](C)N1C(CC2)=CC(Cl)=C2C#N)O)C1=O XRJRDUTWAOVSEZ-VZJVUDMVSA-N 0.000 description 1
- DLESROLPOMKFLJ-FQNRMIAFSA-N CCC([C@](C)(C(C)(C)C1=O)O)N1c(cc1)cc(Cl)c1C#N Chemical compound CCC([C@](C)(C(C)(C)C1=O)O)N1c(cc1)cc(Cl)c1C#N DLESROLPOMKFLJ-FQNRMIAFSA-N 0.000 description 1
- WBVYEUYFHRGIHJ-STQMWFEESA-N CCC[C@@H]([C@H](CC1=O)O)N1c(cc1Cl)ccc1C#N Chemical compound CCC[C@@H]([C@H](CC1=O)O)N1c(cc1Cl)ccc1C#N WBVYEUYFHRGIHJ-STQMWFEESA-N 0.000 description 1
- OUVIHEAWVOBSBQ-UHFFFAOYSA-N CCOC(C1(CC1)C(C(C)N(Cc1ccccc1)Cc1ccccc1)=O)=O Chemical compound CCOC(C1(CC1)C(C(C)N(Cc1ccccc1)Cc1ccccc1)=O)=O OUVIHEAWVOBSBQ-UHFFFAOYSA-N 0.000 description 1
- BAQFOCHVQLGTHX-QUBJWBRDSA-N CC[C@@H](C(C1)=O)N(C(CCC2C#N)CC2Cl)C1=O Chemical compound CC[C@@H](C(C1)=O)N(C(CCC2C#N)CC2Cl)C1=O BAQFOCHVQLGTHX-QUBJWBRDSA-N 0.000 description 1
- ONNRRRLKTSGVFD-VKHMYHEASA-N CC[C@@H](C(O1)=O)NC1=O Chemical compound CC[C@@H](C(O1)=O)NC1=O ONNRRRLKTSGVFD-VKHMYHEASA-N 0.000 description 1
- MTOJCSJQNJRUMD-CABZTGNLSA-N CC[C@@H]([C@@H](C)CC1=O)N1c(c(F)c1C)ccc1C#N Chemical compound CC[C@@H]([C@@H](C)CC1=O)N1c(c(F)c1C)ccc1C#N MTOJCSJQNJRUMD-CABZTGNLSA-N 0.000 description 1
- ADZYJUIFVCKFNE-DOTOQJQBSA-O CC[C@@H]([C@@H](CC1=O)O[SH+](C)(C)C(C)(C)C)N1c(c(C)c1Cl)ccc1C#N Chemical compound CC[C@@H]([C@@H](CC1=O)O[SH+](C)(C)C(C)(C)C)N1c(c(C)c1Cl)ccc1C#N ADZYJUIFVCKFNE-DOTOQJQBSA-O 0.000 description 1
- XAIKVKOBEJOTGL-QPUJVOFHSA-N C[C@@H]([C@H](C1(CC1)C1=O)O)N1c(cc1Cl)ccc1C#N Chemical compound C[C@@H]([C@H](C1(CC1)C1=O)O)N1c(cc1Cl)ccc1C#N XAIKVKOBEJOTGL-QPUJVOFHSA-N 0.000 description 1
- XYKGGRQMRGZMND-SUMWQHHRSA-N C[C@@H]([C@H](C1(CC1)C1=O)O[Si+](C)(C)C(C)(C)C)N1c(cc1Cl)ccc1C#N Chemical compound C[C@@H]([C@H](C1(CC1)C1=O)O[Si+](C)(C)C(C)(C)C)N1c(cc1Cl)ccc1C#N XYKGGRQMRGZMND-SUMWQHHRSA-N 0.000 description 1
- OIVPRZIIQKALPQ-LRDDRELGSA-O C[C@@H]([C@H](CC1=O)O[SH+](C)(C)C(C)(C)C)N1c(cc1Cl)ccc1C#N Chemical compound C[C@@H]([C@H](CC1=O)O[SH+](C)(C)C(C)(C)C)N1c(cc1Cl)ccc1C#N OIVPRZIIQKALPQ-LRDDRELGSA-O 0.000 description 1
- RZUGLLKURVMWKZ-KKMMWDRVSA-N C[C@@H]1NC2OC2C(C)(C)C1=C Chemical compound C[C@@H]1NC2OC2C(C)(C)C1=C RZUGLLKURVMWKZ-KKMMWDRVSA-N 0.000 description 1
- PWAIBFQYNOOUDF-UHFFFAOYSA-N Cc(c(C)c1F)ccc1C#N Chemical compound Cc(c(C)c1F)ccc1C#N PWAIBFQYNOOUDF-UHFFFAOYSA-N 0.000 description 1
- KLJVSSSOHJNLLN-UHFFFAOYSA-N N#Cc(c(Cl)c1)ccc1N(C(CC1CC1)C(O)=C1)C1=O Chemical compound N#Cc(c(Cl)c1)ccc1N(C(CC1CC1)C(O)=C1)C1=O KLJVSSSOHJNLLN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007205966 | 2007-08-07 | ||
| JP205966/07 | 2007-08-07 | ||
| JP2007299658 | 2007-11-19 | ||
| JP299658/07 | 2007-11-19 | ||
| PCT/JP2008/064500 WO2009020234A2 (en) | 2007-08-07 | 2008-08-06 | Pyrrolidin-2 -one derivatives as androgen receptor modulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101821235A CN101821235A (zh) | 2010-09-01 |
| CN101821235B true CN101821235B (zh) | 2012-11-14 |
Family
ID=40329363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801105925A Expired - Fee Related CN101821235B (zh) | 2007-08-07 | 2008-08-06 | 作为雄激素受体调节剂的吡咯烷-2-酮衍生物 |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7834051B2 (https=) |
| EP (1) | EP2176220B1 (https=) |
| JP (1) | JP5292390B2 (https=) |
| KR (1) | KR20100049644A (https=) |
| CN (1) | CN101821235B (https=) |
| AR (1) | AR067823A1 (https=) |
| AU (1) | AU2008284662B2 (https=) |
| BR (1) | BRPI0814957B8 (https=) |
| CA (1) | CA2695852C (https=) |
| CL (1) | CL2008002313A1 (https=) |
| CO (1) | CO6160326A2 (https=) |
| CR (1) | CR11266A (https=) |
| CY (1) | CY1114067T1 (https=) |
| DK (1) | DK2176220T3 (https=) |
| DO (1) | DOP2010000053A (https=) |
| EA (1) | EA017429B1 (https=) |
| ES (1) | ES2406685T3 (https=) |
| GE (1) | GEP20125571B (https=) |
| HR (1) | HRP20130374T1 (https=) |
| JO (1) | JO2864B1 (https=) |
| MA (1) | MA31639B1 (https=) |
| ME (1) | ME01579B (https=) |
| MX (1) | MX2010001484A (https=) |
| MY (1) | MY159910A (https=) |
| NZ (1) | NZ583624A (https=) |
| PE (1) | PE20090899A1 (https=) |
| PL (1) | PL2176220T3 (https=) |
| PT (1) | PT2176220E (https=) |
| RS (1) | RS52812B (https=) |
| SI (1) | SI2176220T1 (https=) |
| TN (1) | TN2010000062A1 (https=) |
| TW (1) | TWI418543B (https=) |
| WO (1) | WO2009020234A2 (https=) |
| ZA (1) | ZA201001289B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2176220T3 (pl) * | 2007-08-07 | 2013-08-30 | Takeda Pharmaceuticals Co | Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| ES2488990T3 (es) * | 2008-02-22 | 2014-09-01 | Radius Health, Inc. | Moduladores selectivos del receptor de andrógenos |
| WO2009119880A1 (en) * | 2008-03-26 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Substituted pyrazole derivatives and use thereof |
| MX338831B (es) | 2010-02-04 | 2016-05-03 | Radius Health Inc | Moduladores selectivos de receptores de androgenos. |
| EP2568806B1 (en) | 2010-05-12 | 2016-05-11 | Radius Health, Inc. | Therapeutic regimens |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2013152170A1 (en) * | 2012-04-04 | 2013-10-10 | Catylix, Inc. | Selective androgen receptor modulators |
| EP3378472A1 (en) | 2012-08-09 | 2018-09-26 | Dynamis Therapeutics, Inc. | Combinations of meglumine |
| US9868905B2 (en) | 2012-09-21 | 2018-01-16 | Merck Patent Gmbh | Compounds having a C—C triple bond and use thereof in liquid-crystal mixtures |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| FI3834824T3 (fi) | 2014-03-28 | 2025-12-05 | Univ Duke | Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla |
| KR101597327B1 (ko) * | 2014-04-24 | 2016-02-24 | 동아에스티 주식회사 | 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제 |
| CN103951688B (zh) * | 2014-05-06 | 2016-04-20 | 成都安斯利生物医药有限公司 | 一种制备3,5-二氟-4-甲基苯硼酸的方法 |
| LT3474841T (lt) | 2016-06-22 | 2022-06-10 | Ellipses Pharma Ltd | Ar+ krūties vėžio gydymo būdai |
| KR102707399B1 (ko) | 2017-01-05 | 2024-09-13 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| IL279853B2 (en) | 2018-07-04 | 2025-01-01 | Radius Pharmaceuticals Inc | Polymorphic forms of RAD 1901-2HCL |
| JP7446316B2 (ja) | 2019-01-11 | 2024-03-08 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換ピロリジンアミドｉｉｉ |
| CN113348163B (zh) | 2019-02-12 | 2024-10-08 | 雷迪厄斯制药公司 | 方法和化合物 |
| CN110204505B (zh) * | 2019-05-31 | 2023-02-03 | 荆门医药工业技术研究院 | (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺 |
| US20230012570A1 (en) * | 2019-11-20 | 2023-01-19 | Medshine Discovery Inc. | Bicyclic compound used as selective androgen receptor modulator |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1319091A (zh) * | 1998-09-22 | 2001-10-24 | 山之内制药株式会社 | 氰基苯基衍生物 |
| WO2005090282A1 (en) * | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| WO2005108351A1 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Benzonitrile derivatives to treat musculoskeletal frailty |
| WO2006117677A1 (en) * | 2005-05-05 | 2006-11-09 | Warner-Lambert Company Llc | Androgen modulators |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4141399A1 (de) | 1991-12-16 | 1993-06-17 | Bayer Ag | 4-(substituierte)amino-3-arylpyrrolinon-derivate |
| US6258833B1 (en) | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US7547728B2 (en) | 2001-12-06 | 2009-06-16 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
| US7026500B2 (en) | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| JP2002088073A (ja) | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
| FR2817472B1 (fr) | 2000-12-06 | 2003-01-03 | Oreal | Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre |
| EP1466902A4 (en) | 2001-12-28 | 2005-11-09 | Takeda Pharmaceutical | ANTAGONISTS OF THE ANDROGEN RECEPTOR |
| JP4316232B2 (ja) | 2001-12-28 | 2009-08-19 | 武田薬品工業株式会社 | アンドロゲン受容体拮抗剤 |
| GEP20074191B (en) | 2002-06-17 | 2007-09-10 | Univ Tennessee Res Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
| BR0313405A (pt) | 2002-08-12 | 2005-07-12 | Takeda Pharmaceutical | Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto |
| GB0402492D0 (en) | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
| CA2566942A1 (en) | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| ATE552235T1 (de) | 2004-06-07 | 2012-04-15 | Univ Tennessee Res Foundation | Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür |
| NZ555974A (en) | 2005-01-10 | 2010-11-26 | Acadia Pharm Inc | Aminophenyl derivatives as selective androgen receptor modulators |
| DK1891038T3 (da) | 2005-05-13 | 2009-01-19 | Lilly Co Eli | Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer |
| EP1911743B8 (en) | 2005-08-01 | 2013-01-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| EP1987827A1 (en) | 2006-02-20 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Novel pharmaceutical |
| CA2658098A1 (en) * | 2006-07-19 | 2008-01-24 | Osurf | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| KR20090034395A (ko) | 2006-07-26 | 2009-04-07 | 노파르티스 아게 | 운데카프레닐 피로포스페이트 합성효소의 억제제 |
| CA2670976C (en) | 2006-11-30 | 2015-01-27 | Atsushi Hasuoka | Cyclic amine compound |
| PL2176220T3 (pl) | 2007-08-07 | 2013-08-30 | Takeda Pharmaceuticals Co | Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego |
-
2008
- 2008-08-06 PL PL08792430T patent/PL2176220T3/pl unknown
- 2008-08-06 ES ES08792430T patent/ES2406685T3/es active Active
- 2008-08-06 HR HRP20130374AT patent/HRP20130374T1/hr unknown
- 2008-08-06 US US12/221,739 patent/US7834051B2/en active Active
- 2008-08-06 GE GEAP200811715A patent/GEP20125571B/en unknown
- 2008-08-06 DK DK08792430.4T patent/DK2176220T3/da active
- 2008-08-06 RS RS20130235A patent/RS52812B/sr unknown
- 2008-08-06 SI SI200830941T patent/SI2176220T1/sl unknown
- 2008-08-06 ME MEP-2013-64A patent/ME01579B/me unknown
- 2008-08-06 US US12/672,516 patent/US8420694B2/en not_active Expired - Fee Related
- 2008-08-06 KR KR1020107005062A patent/KR20100049644A/ko not_active Abandoned
- 2008-08-06 MX MX2010001484A patent/MX2010001484A/es active IP Right Grant
- 2008-08-06 CL CL2008002313A patent/CL2008002313A1/es unknown
- 2008-08-06 NZ NZ583624A patent/NZ583624A/en not_active IP Right Cessation
- 2008-08-06 CN CN2008801105925A patent/CN101821235B/zh not_active Expired - Fee Related
- 2008-08-06 BR BRPI0814957A patent/BRPI0814957B8/pt not_active IP Right Cessation
- 2008-08-06 EP EP08792430A patent/EP2176220B1/en active Active
- 2008-08-06 CA CA2695852A patent/CA2695852C/en active Active
- 2008-08-06 AR ARP080103428A patent/AR067823A1/es unknown
- 2008-08-06 AU AU2008284662A patent/AU2008284662B2/en not_active Ceased
- 2008-08-06 PT PT87924304T patent/PT2176220E/pt unknown
- 2008-08-06 TW TW097129774A patent/TWI418543B/zh not_active IP Right Cessation
- 2008-08-06 PE PE2008001314A patent/PE20090899A1/es not_active Application Discontinuation
- 2008-08-06 EA EA201070246A patent/EA017429B1/ru unknown
- 2008-08-06 MY MYPI2010000564A patent/MY159910A/en unknown
- 2008-08-06 WO PCT/JP2008/064500 patent/WO2009020234A2/en not_active Ceased
- 2008-08-06 JP JP2010504096A patent/JP5292390B2/ja not_active Expired - Fee Related
- 2008-08-09 JO JO2008353A patent/JO2864B1/en active
-
2010
- 2010-02-05 TN TNP2010000062A patent/TN2010000062A1/fr unknown
- 2010-02-05 DO DO2010000053A patent/DOP2010000053A/es unknown
- 2010-02-12 CR CR11266A patent/CR11266A/es unknown
- 2010-02-23 ZA ZA2010/01289A patent/ZA201001289B/en unknown
- 2010-02-26 MA MA32657A patent/MA31639B1/fr unknown
- 2010-03-05 CO CO10026475A patent/CO6160326A2/es unknown
-
2013
- 2013-06-21 CY CY20131100507T patent/CY1114067T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1319091A (zh) * | 1998-09-22 | 2001-10-24 | 山之内制药株式会社 | 氰基苯基衍生物 |
| WO2005090282A1 (en) * | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| WO2005108351A1 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Benzonitrile derivatives to treat musculoskeletal frailty |
| WO2006117677A1 (en) * | 2005-05-05 | 2006-11-09 | Warner-Lambert Company Llc | Androgen modulators |
Non-Patent Citations (1)
| Title |
|---|
| JP特开2002-88073A 2002.03.27 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101821235B (zh) | 作为雄激素受体调节剂的吡咯烷-2-酮衍生物 | |
| JP5070054B2 (ja) | 環状アミン化合物 | |
| WO2009133861A1 (ja) | 環状アミン化合物 | |
| CN104230865B (zh) | 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途 | |
| WO2007097289A1 (ja) | 新規医薬 | |
| TW202330513A (zh) | )抑制劑及其使用方法 | |
| JP5241507B2 (ja) | 環状アミン化合物 | |
| HK1143972B (en) | Pyrrolidin-2-one derivatives as androgen receptor modulator | |
| CA3118438A1 (en) | Novel imidazole compounds, process for the synthesis and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121114 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |